ResultsIQ › Latest results › Nephrocare Health Services Limited
Nephrocare Health Services Limited Q2 FY27 earnings call summary
NSE: NEPHROPLUS · BSE: 544647
Earnings call of 4 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue ₹303 cr, up 23.5%, with medium-term guidance of 15% to 20% revenue growth reiterated as margins compress about 80 basis points.
Key takeaways
- Q2 revenue ₹303 cr, up 23.5% year on year; H1 revenue ₹585 cr, up 23.6%.
- Guidance Medium-term revenue growth of 15% to 20% over three to four years reiterated; no annual guidance given.
- Margin change H1 FY27 EBITDA margin 23.0% against FY26 23.8%, about 80 basis points lower on new-country investment.
- Growth driver International mix reached about 47% of revenue, up from 42% in FY26, lifting revenue per treatment.
- Main risk Saudi tender has a binary outcome and management cannot assure winning a region.
Nephrocare Health Services Limited Q2 FY27 results
As filed: Revenue ₹303 cr, EBITDA ₹67.1 cr, PAT ₹33.5 cr, EBITDA margin 22.1%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹303 cr). Scored once a year-earlier consolidated quarter exists.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.9% in 30 days (Nifty 500: −3.1%).
- Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
- Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).
Past price moves after results do not indicate future moves. Not a recommendation.
Nephrocare Health Services Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (4 Nov 2026), Results deck (3 Nov 2026), Results press release (3 Nov 2026)
- Q1 FY27: Earnings call (12 Aug 2026), Results deck (11 Aug 2026), Results press release (11 Aug 2026)
- Q4 FY26: Earnings call (20 May 2026), Results deck (19 May 2026), Results press release (19 May 2026)
- Q3 FY26: Earnings call (11 Feb 2026), Results deck (10 Feb 2026), Results press release (10 Feb 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.